Q-Line Biotech IPO Details
Q-Line Biotech IPO Summary
Q-Line Biotech IPO DRHP (Draft Red Herring Prospectus) has been Exchange Approval Received.
Q-Line Biotech IPO total issue size comprises 70,53,200 shares (aggregating up to ₹0.00 Cr.). This includes a fresh issue of 70,53,200 shares (aggregating up to ₹0.00 Cr.).
Q-Line Biotech IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
The Lead Managers for Q-Line Biotech IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Hem Securities Ltd, Share India Capital Services Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Q-Line Biotech Limited DRHP.
Q-Line Biotech IPO Details
Q-Line Biotech IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| To be announced | |||
Q-Line Biotech IPO Reservation
Promoter Holding
Documents
Q-Line Biotech IPO Valuations
Q-Line Biotech Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 455.49 | 339.25 | 251.58 |
| Total Income | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 28.13 | 34.44 | 32.10 |
| EBITDA | 71.32 | 37.63 | 32.98 |
| NET Worth | 189.95 | 161.81 | 127.37 |
| Reserves and Surplus | 188.37 | 160.24 | 125.79 |
| Total Borrowing | 164.95 | 96.91 | 73.65 |
| Amount in ₹ Crore | |||
About Q-Line Biotech IPO
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs.
The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges.
The company's key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices.
As of March 31, 2025, the company had 313 permanent employees.
Strength Of Q-Line Biotech IPO
Risk Of Q-Line Biotech IPO
Objectives Q-Line Biotech IPO
1. To meet Working Capital requirements
2. Repayment of certain borrowing availed by the Company, in part or full
3. General Corporate Purpose
Company Contact Details
Q-Line Biotech Ltd.
298-281,
Transport Nagar,
Kanpur Road Adjacent Transport Nagar Metro Station
Lucknow, Uttar Pradesh, 226012
Phone: +91 522-2435570
Email: compliance@qlinebiotech.com
Website: https://qlinebiotech.com/
Registrar Contact Details
Market Maker
Q-Line Biotech FAQs
The Q-Line Biotech IPO is a SME public issue comprising 7053200 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹0.00 Cr.. The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
Purva Sharegistry India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the NSE
As of now, the current GMP stands at TBA.
Quick Links
Comments
